Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstract
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Addendum
Announcement
Art & Psychiatry
Article
Articles
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Commentary
Conference Oration
Conference Summary
Continuing Medical Education
Correspondence
Corrigendum
Cosmetic Dermatology
Cosmetology
Current Best Evidence
Current View
Derma Quest
Dermato Surgery
Dermatopathology
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
e-IJDVL
Editor Speaks
Editorial
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Errata
Erratum
Focus
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
General
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
History
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL AWARDS 2015
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL International Awards 2018
Images in Clinical Practice
In Memorium
Inaugural Address
Index
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
LETTER TO THE EDITOR - LETTERS IN RESPONSE TO PUBLISHED ARTICLES
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Medicolegal Window
Messages
Miscellaneous Letter
Musings
Net Case
Net case report
Net Image
Net Letter
Net Quiz
Net Study
New Preparations
News
News & Views
Obituary
Observation Letter
Observation Letters
Oration
Original Article
ORIGINAL CONTRIBUTION
Original Contributions
Pattern of Skin Diseases
Pearls
Pediatric Dermatology
Pediatric Rounds
Perspective
Presedential Address
Presidential Address
Presidents Remarks
Quiz
Recommendations
Regret
Report
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Retraction
Review
Review Article
Review Articles
Revision Corner
Self Assessment Programme
SEMINAR
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Special Article
Specialty Interface
Studies
Study Letter
Supplement-Photoprotection
Supplement-Psoriasis
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
SYMPOSIUM - VITILIGO
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Tables
Technology
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapeutics
Therapy
Therapy Letter
View Point
Viewpoint
What’s new in Dermatology
View/Download PDF
Letter to the Editor - Therapy Letter
2016:82:3;345-347
doi: 10.4103/0378-6323.174389
PMID: 27088952

Effective treatment of severe nail psoriasis using topical calcipotriol with betamethasone dipropionate gel

Eugene Sern-Ting Tan, Hazel Hwee-Boon Oon
 National Skin Centre, Singapore

Correspondence Address:
Eugene Sern-Ting Tan
National Skin Centre, 1 Mandalay Road
Singapore
How to cite this article:
Tan ES, Oon HH. Effective treatment of severe nail psoriasis using topical calcipotriol with betamethasone dipropionate gel. Indian J Dermatol Venereol Leprol 2016;82:345-347
Copyright: (C)2016 Indian Journal of Dermatology, Venereology, and Leprology

Sir,

Nail psoriasis poses a therapeutic challenge. We report a 48-year-old Chinese man, with chronic plaque psoriasis and psoriatic arthropathy, who was seen at the National Skin Centre in Singapore. He was troubled by significant nail involvement despite methotrexate therapy and had a high baseline nail psoriasis severity index score of 62 [Figure - 1]a and [Figure - 1]b.[1] His past medical history included diabetes mellitus, hypertension, hyperlipidemia and gout. His cutaneous psoriasis had remained stable with a body surface area of 5%. He was receiving oral methotrexate 10 mg weekly for psoriatic arthropathy from his rheumatologist.

Figure 1: (a) Severe changes of nail psoriasis pretreatment, manifested by distal onycholysis, subungual hyperkeratosis, pitting and yellowish discoloration with a baseline nail psoriasis severity index score of 62. (b) Close-up view of patient's thumbnails

Topical calcipotriol 50 mcg/g with betamethasone diproprionate 0.5 mg/g combination gel once daily was applied to the proximal nail fold and distal nail bed. Shortly thereafter, his methotrexate was abruptly discontinued for 6 weeks due to a shortage of the medication. Consequently, he experienced a flare of his cutaneous psoriasis.

Despite being off methotrexate for 6 weeks, his nail psoriasis improved on treatment with calcipotriol with betamethasone diproprionate gel. There was reduction of pitting, yellowish discoloration, onycholysis and subungual hyperkeratosis. The nail psoriasis severity index decreased to 37 score after 6 weeks of application of the gel [Figure - 2]a and [Figure - 2]b. Both nail matrix and nail bed disease showed marked improvement with scores decreasing from 38 to 18 and 24 to 19, respectively. The results were sustained when methotrexate was resumed for 11 weeks and calcipotriol with betamethasone diproprionate gel was used for a total of 22 weeks. At week 22, his final nail psoriasis severity index score was 31.

Figure 2: (a) Signifi cant improvement in nail disease after 6 weeks of treatment with calcipotriol and betamethasone dipropionate gel with nail psoriasis severity index reducing to 37. (b) Close-up view of patient's thumbnails

In patients, who have uncomplicated nail psoriasis with absent or mild cutaneous psoriasis, the first line of treatment is topical therapy. However, the topical treatment of nail psoriasis remains challenging for some reasons.[2] First, the nail plate presents a formidable barrier that limits the penetration of topical drugs to target sites in the nail bed and matrix. Second, poor adherence to topical treatment is a common as early nail disease is frequently asymptomatic and clinical improvement is slow. Third, there is a relative dearth of quality clinical evidence on the efficacy of various topical therapies for nail psoriasis.

Currently, the most widely used topical agents for the treatment of nail psoriasis are corticosteroids and vitamin D3 analogs while intralesional injection of corticosteroids may be considered for patients with limited nail psoriasis. In an open-label study, a nightly regimen of calcipotriol cream on weekdays and clobetasol propionate cream on weekends for 6 months reduced subungual hyperkeratosis by 70%.[3] A double-blind, randomized controlled trial demonstrated that calcipotriol ointment was as effective as betamethasone dipropionate with salicylic acid in improving nail bed hyperkeratosis by 50% after 5 months of twice daily application.[4] Rigopoulos et al. conducted an open-label study on 22 patients with 114 psoriatic nails treated with the two-compound formulation of calcipotriol plus betamethasone dipropionate ointment once daily for 12 weeks, and showed a mean improvement of 72% in nail psoriasis severity index.[5] Other topical therapies with reported efficacy include 5-fluorouracil, dithranol, tacrolimus and tazarotene.[2] Aside from topical therapy, other therapeutic modalities for nail psoriasis include radiation therapy and systemic agents such as methotrexate, ciclosporin, acitretin and biologic therapy.[2] The choice of treatment should be individualized based on the severity of nail psoriasis, extent of cutaneous and/or joint disease, co-morbidities and individual preferences of the patient.

The gel formulation of calcipotriol with betamethasone diproprionate is licensed for use in scalp psoriasis but has been used anecdotally for treating nail psoriasis. In our patient, nail psoriasis responded well to calcipotriol with betamethasone dipropionate gel applied once daily with nail psoriasis severity index score reducing by 50% from 62 to 31 in 6 months. The treatment was well tolerated, and there was no evidence of any adverse effects such as steroid atrophy at the time of his last review. This two-compound formulation integrates the anti-inflammatory properties of a potent corticosteroid with the immunomodulatory effects of a vitamin D3 analog. As a gel, it is more cosmetically elegant than an ointment and allows superior access to the nail bed when applied to the nail folds and hyponychium in onycholytic nails. The once-daily regimen confers the advantage of better treatment adherence which is important as topical treatment needs to be prolonged for several months to achieve optimal clinical response.

We were unable to find any previous reports showing therapeutic efficacy of calcipotriol with betamethasone dipropionate gel in the treatment of nail psoriasis. Our case suggests that this treatment may be considered a useful addition to the armamentarium of topical drugs for treating nail psoriasis.

Financial support and sponsorship

Nil.

Conflicts of interest

Dr. Eugene Sern-Ting Tan has received sponsorship for overseas meetings by AbbVie, Janssen Pharmaceuticals and LEO Pharma. Dr. Hazel Hwee-Boon Oon has received honoraria, grants and acted as a speaker and/or investigator for AbbVie, Galderma, Janssen Pharmaceuticals, LEO Pharma, Novartis and Pfizer.

References
1.
Rich P, Scher RK. Nail psoriasis severity index: A useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003;49:206-12.
[Google Scholar]
2.
Tan ES, Chong WS, Tey HL. Nail psoriasis: A review. Am J Clin Dermatol 2012;13:375-88.
[Google Scholar]
3.
Rigopoulos D, Ioannides D, Prastitis N, Katsambas A. Nail psoriasis: A combined treatment using calcipotriol cream and clobetasol propionate cream. Acta Derm Venereol 2002;82:140.
[Google Scholar]
4.
Tosti A, Piraccini BM, Cameli N, Kokely F, Plozzer C, Cannata GE, et al. Calcipotriol ointment in nail psoriasis: A controlled double-blind comparison with betamethasone dipropionate and salicylic acid. Br J Dermatol 1998;139:655-9.
[Google Scholar]
5.
Rigopoulos D, Gregoriou S, Daniel Iii CR, Belyayeva H, Larios G, Verra P, et al. Treatment of nail psoriasis with a two-compound formulation of calcipotriol plus betamethasone dipropionate ointment. Dermatology 2009;218:338-41.
[Google Scholar]

Fulltext Views
112

PDF downloads
44
Show Sections